We studied 63 patients with myasthenia gravis (MG) requiring treatment with intravenous immunoglobulin, to determine if polymorphisms within the FCγR2A (rs1801274), FCγR2B (rs1050501), FCγR3A (rs396991), and FCγR3B (NA1/NA2) genes are correlated with response to treatment. There was no significant difference in any of the polymorphisms studied between responders and nonresponders. Patients with the FCγR2B-232I/I polymorphism had higher disease severity measured by the quatitative myasthenia gravis score (QMGS). There was no difference in the distribution of the FCγR2B-232 polymorphisms between the patients and 90 healthy controls. The finding of greater disease severity in patients with the FCγR2B-232I/I polymorphism requires confirmation in a larger population of patients with myasthenia gravis.
*Division of Neurology, Department of Medicine, University Health Network, Toronto General Hospital
†Tanz Centre for Research in Neurodegenerative Diseases
‡Department of Medicine, University of Toronto, Toronto, Canada
§Cambridge Institute for Medical Research
¶Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
Reprints: Vera Bril, MD, FRCP, 5EC-309, Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4 (e-mail: firstname.lastname@example.org).
Hans Katzberg reports an unrestricted educational grant from Talecris Biotherapeutics for clinician-initiated research. Vera Bril reports an unrestricted educational grant from Talecris Biotherapeutics for clinician-initiated research and consultancy work for Talecris Biotherapeutics, CSL, Eli Lilly, and Pfizer. The other authors declare no conflicts of interest.